NanoViricides Inc (NNVC) is a Healthcare · Biotechnology company listed on NYSE MKT. Price $1.46 (+4.29%), Market cap $0.04B, 52-week low–high $0.85 ~ $2.03.
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediat
Financial statements, price targets, institutional (13F) holdings and related news for NanoViricides Inc are updated in real time on BlackAll Trade.
NanoViricides Inc trades at $1.46 (+4.29%). Real-time quotes and charts are available on BlackAll Trade.
NanoViricides Inc has a market cap of about $0.04B.
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug can